AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA...

Related Keywords

Puerto Rico , United States , Amsterdam , Noord Holland , Netherlands , Colorado , America , Arterioscler Thromb Vasc , Clin Lipidol , Jessica Akopyan , Johns Hopkins , Coll Cardiol , C Michael Gibson , Prnewswire Amgen , Michellel Odonoghue , Justin Claeys , Paul Burton , Teneobio Inc , Beigene Ltd , Exchange Commission , Nasdaq , Amgen , Institute Of Clinical Research , Drug Administration , Harvard Medical School , Linkedin , Extension Program On Long , European Society Of Cardiology , Twitter , Awareness To Action Implementation Consortium , Instagram , Youtube , Chemocentryx Inc , University Of Colorado , Kyowa Kirin Co Ltd , Innovative Lipid Management , Olpasiran Phase , Demonstrates Continued Reduction , Year After , Action Implementation Consortium , Late Breaking Science Session , European Society , Annual Meeting , Cardiovascular Medicine , Action Implementation , Clinical Research , Oxidized Phospholipids , Primary Results , Long Term Efficacy , Coronary Artery Disease , Elevated Lipoprotein , Outcomes Trial , Sponsored Studies , Major Adverse Limb Events , Stable Atherosclerotic Vascular Disease , Olpasiran Trials , Cardiovascular Events And Lipoprotein , Dow Jones Industrial Average , Horizon Therapeutics , Federal Trade Commission , Thromb Vasc ,